Hisanobu Niitani

Learn More
To determine a standard combination chemotherapy for patients with advanced non-small-cell lung cancer (NSCLC), we conducted a phase III trial of irinotecan (CPT-11) to test the hypotheses that CPT-11+cisplatin is superior to cisplatin+vindesine and that CPT-11 monotherapy is not inferior to cisplatin+vindesine. A total of 398 patients with previously(More)
A phase I trial of the combination of irinotecan (CPT-11) with cisplatin in advanced non-small cell lung cancer (NSCLC) showed a very promising response rate of 54% in previously untreated NSCLC patients. This study was conducted to confirm the activity and toxicities of CPT-11 and cisplatin combination for previously untreated NSCLC in a(More)
The purpose of this study was to evaluate the efficacy and safety of a novel oral anticancer fluoropyrimidine derivative, S-1, in patients receiving initial chemotherapy for unresectable, advanced non-small-cell lung cancer (NSCLC). Between June 1996 and July 1998, 62 patients with NSCLC who had not received previous chemotherapy for advanced disease were(More)
In order to study the relationship between tumor transplantability to the nude mouse and abnormality of the myc family genes (c-myc, N-myc, L-myc) in human primary lung cancers, 32 various lung cancers were analyzed for abnormality of the myc family genes by Southern blot hybridization, and were transplanted s.c. into nude mice. Southern blot analysis(More)
NUMEROUS STUDIES have revealed that bacterial adjuvants such as BCoG and BCG cell-wall skeletons have strong anti-tumour activity for animal tumours and also for human malignancies (Ogura et al., 1978; Sarna et al., 1978; Yamamura et al., 1979). These bacterial adjuvants are presumed to activate mainly macrophages and lymphocytes, and render them toxic(More)
PURPOSE To evaluate the efficacy and toxicity of a novel combination treatment using concurrent radiotherapy with cisplatin plus UFT, which is comprised of uracil and tegafur, in locally advanced non-small cell lung cancer (NSCLC) patients. EXPERIMENTAL DESIGN In this Phase II trial, patients with unresectable stage III NSCLC were treated with the oral(More)
We performed MRI on 57 socially active, healthy people without neurologic signs or symptoms when admitted to our hospital for a routine medical evaluation. Of these, 34 persons had patchy white matter lesions (PWMLs). Mild lesions were distributed mainly around the anterior horns or the bodies of the lateral ventricles. However, more severe lesions were(More)
  • 1